Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2023-05-09 Earnings Release
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2023, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2023. The text explicitly states that the press release is furnished as an exhibit to this Form 8-K and that the information is not deemed "filed" for certain regulatory purposes. The document itself is short (3868 characters) and primarily serves as a notification of the earnings release rather than containing the full financial results or detailed analysis. According to the "MENU VS MEAL" rule, such a document is an announcement of a report (the earnings release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER).
2023-05-09 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-09 English
ARS
Annual Report
2023-04-28 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes details about the annual general meeting (AGM), proposals to be voted on, board recommendations, and instructions for shareholders to access proxy materials and vote. It does not contain the actual proxy statement or annual report but serves as a notice and overview of proxy materials availability and voting instructions. Therefore, it is classified as Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not a brief announcement or a full report but proxy solicitation materials.
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It includes detailed information about the meeting agenda, voting proposals, board appointments, and instructions for shareholders to vote. The document references the 2023 Annual General Meeting of Shareholders and includes the Notice of Meeting and Proxy Statement materials. It is not the Annual Report itself, nor an earnings release or other financial report. The presence of voting proposals and detailed meeting information aligns with the definition of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement, not just an announcement or a brief notice. Therefore, the correct classification is PSI with high confidence.
2023-04-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.